Diasorin traded at 58.26 this Saturday March 28th, decreasing 0.96 or 1.62 percent since the previous trading session. Looking back, over the last four weeks, Diasorin lost 17.90 percent. Over the last 12 months, its price fell by 36.33 percent. Looking ahead, we forecast Diasorin to be priced at 56.44 by the end of this quarter and at 51.30 in one year, according to Trading Economics global macro models projections and analysts expectations.
DiaSorin SpA is an Italy-based company engaged in healthcare industry. The Company specializes in provision of developing, producing and commercializing reagent kits for the in vitro diagnostics. The Company develops and manufactures reagents for in vitro diagnostics and produces products for the fields of infectious disease, hepatitis, endocrinology, bone & mineral metabolism, cancer, brain injury, cardiac, therapeutic drug monitoring and autoimmunity. The Company’s business activities are divided into two markets. The Immunodiagnostics market develops, produces and markets immunoreagent kits, which are based on three techniques: Chemiluminescence (CLIA), Colorimetry (ELISA) and Radioimmunometry (RIA). The Molecular Diagnostics market supplies end laboratories with an automated result to perform the three steps for the final diagnostic result, including nucleic acids extraction, amplification and diagnosis. It operates through ELISA immunodiagnostic business portfolio.